Previous 10 | Next 10 |
Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications. Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk pro...
Psychedelics could be one of the most rewarding opportunities of 2021 and beyond. All as countless studies show how useful they can be in treating mental health issues, such as o bsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, and anxiety . ...
TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that during the month of November management will attend the Microdose Wonderland: M...
TORONTO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for the fiscal second quarter ended Septe...
NetworkNewsWire Editorial Coverage : There isn’t a cigarette smoker in the world who doesn’t know smoking is bad for them. The problems are that nicotine is one of the most highly addictive substances in the world, and for the nearly 70% of 34.1 million Americans who want ...
Bad news for Apple and Amazon turned into good news for Microsoft (NASDAQ:MSFT) on Friday. While two of the software giant's megacap rivals suffered earnings-inspired declines, MSFT rose to a new 52-week high and took the crown as the world's largest company by market cap. Want to hear someth...
Palm Beach, FL –October 28, 2021 – FinancialNewsMedia.com News Commentary – Psychedelic drugs such as psilocybin, LSD and MDMA have tremendous medical and commercial future potential… and for ketamine, the “future” is now. Drug developer...
“Magic mushrooms may be the biggest advance in treating depression since Prozac,” says Newsweek. Not only has the US FDA granted “breakthrough status” to psilocybin, dozens of medical studies are seeing positive study results, including Johns Hopkins Medicine and...
TORONTO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their Seattle clinic, their sixth in the United States, along with the recent ...
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Oct. 18, ...
News, Short Squeeze, Breakout and More Instantly...
Field Trip Health Ltd. Company Name:
FTRP Stock Symbol:
NASDAQ Market:
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the " Company " or “ Reunion ”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outco...
Field Trip Health has changed its name to Reunion Neuroscience Inc. (TSX: FTRP)(Nasdaq: FTRP) and reported its fiscal first quarter 2023 results for the period ending June 30, 2022. Reunion reported expenses of $5 million and a net loss of $13 million. The increase in net loss...
Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies. Field Trip Discovery renamed Reunion Neuroscience Inc. (“ Reunion ” or the “ Company ”), and will remain listed on t...